Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
United States Gastric Cancer Diagnostic Procedure Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Types (Symptomatic and Asymptomatic), Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue, and Others), Procedures (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays, and Others), Offerings (Instruments, Reagents & Consumables, and Services), and Disease Indication (Early Gastric Cancer and Advanced Gastric Cancer)
- Report Code : TIPRE00029824
- Pages : 158
The United States gastric cancer diagnostic procedure market size is expected to reach US$ 637.84 million by 2028 from US$ 481.37 million in 2022. The market is estimated to record a CAGR of 4.8% from 2022 to 2028.
The rising prevalence of gastrointestinal diseases and the growing geriatric population in the US are contributing to the growth of the United States gastric cancer diagnostic procedure market size. However, the shortage of medical laboratory professionals is hampering the market growth.
Rising Geriatric Population in US Drives United States Gastric Cancer Diagnostic Procedure Market Growth
As per the Fact Sheet: Aging in the United States, the number of people aged 65 and above is estimated to increase from 52 million in 2018 to 95 million by 2060. Additionally, the 65-year-old age group’s share of the total population will increase from 16% in 2018 to 23% by 2060. Further, as per the US Census Bureau, all the baby boomers will be older than 65 years in the US by 2030 and will hold 21% of the population. It also mentioned that by 2060, around one in four people in the US will be aged 65 years and above, the number of people aged 85 and above will triple, and the country will add half a million centenarians. The prevalence of gastrointestinal disorders is high in the adult and elderly populations. As the aging population rises, the disease burden also increases. Thus, an increasing aging population propels the demand for gastric cancer diagnostics, thereby bolstering the growth of the gastric cancer diagnostic procedure market.
Based on symptom type, the United States gastric cancer diagnostic procedure market is bifurcated into symptomatic and asymptomatic. The asymptomatic segment held a larger share of the market in 2022. However, the symptomatic segment is anticipated to register a higher CAGR in the market during the forecast period. The symptoms of the early stages of gastric cancer may include indigestion, stomach discomfort, bloating, mild nausea, appetite loss, and heartburn. The advanced stages of gastric cancer show symptoms such as blood in the stool, vomiting, weight loss, stomach pain, jaundice, ascites (build-up of fluid in the abdomen), and trouble swallowing. Based on healthcare providers, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, others. In 2022, the hospitals segment held the largest share of the United States gastric cancer diagnostic procedure market. The market for the cancer research institutes segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, by body fluid, is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. In 2021, the blood segment held the largest share of the market. However, the market for the tissue segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics and immunoassays, and others. In 2021, the imaging tests segment held the largest share of the market. The market for the biopsy and tissue tests segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on offerings, is segmented into instruments, reagents and consumables, and services. In 2021, the reagents and consumables segment held the largest share of the market. The market for the services segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on disease indication, is segmented into early gastric cancer and advanced gastric cancer. In 2021, the advanced gastric cancer segment held a larger share of the market. The market for the same segment is expected to grow at a higher rate in the coming years.
The International Foundation for Gastrointestinal Disorders, American Institute for Cancer Research, Centers for Disease Control and Prevention, U.S. Census Bureau, and Population Reference Bureau are among the major primary and secondary sources referred to while preparing the report on the United States gastric cancer diagnostic procedure market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Gastric Cancer Diagnostic Procedure Market – By Healthcare Providers
1.3.2 Gastric Cancer Diagnostic Procedure Market – By Symptom Types
1.3.3 Gastric Cancer Diagnostic Procedure Market – By Body Fluid
1.3.4 Gastric Cancer Diagnostic Procedure Market – By Procedures
1.3.5 Gastric Cancer Diagnostic Procedure Market – By Offerings
1.3.6 Gastric Cancer Diagnostic Procedure Market – By Disease Indication
1.3.7 Gastric Cancer Diagnostic Procedure Market – By Country
2. Gastric Cancer Diagnostic Procedure Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Gastric Cancer Diagnostic Procedure Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 US – PEST Analysis
4.3 Expert Opinion
4.4 Gastric Cancer Prevalence Statistics
4.5 Pre-Diagnosis Workflow
4.6 Post-Diagnosis Workflow
5. United States Gastric Cancer Diagnostic Procedure Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Growing Geriatric Population in US
5.2 Market Restraints
5.2.1 Shortage of Medical Laboratory Professionals
5.3 Market Opportunities
5.3.1 Rising Awareness on Gastric Cancer
5.4 Future Trends
5.4.1 Development of AI-Based Gastric Cancer Diagnostic Platform
5.5 Impact Analysis
6. Gastric Cancer Diagnostic Procedure Market – US Analysis
6.1 United States Gastric Cancer Diagnostic Procedure Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players
7. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Healthcare Providers
7.1 Overview
7.2 Diagnostic Laboratories
7.2.1 Overview
7.2.2 Diagnostic Laboratories: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
7.2.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Diagnostic Laboratories, by Type, 2019–2028 (US$ Million)
7.3 Hospitals
7.3.1 Overview
7.3.2 Hospitals: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Hospitals, by Type, 2019–2028 (US$ Million)
7.4 Cancer Research Institutes
7.4.1 Overview
7.4.2 Cancer Research Institutes: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Cancer Research Institutes, by Type, 2019–2028 (US$ Million)
7.5 Oncology Specialty Clinics
7.5.1 Overview
7.5.2 Oncology Specialty Clinics: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Oncology Specialty Clinics, by Type, 2019–2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Others, by Type, 2019–2028 (US$ Million)
8. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Symptom Type
8.1 Overview
8.2 Symptomatic
8.2.1 Overview
8.2.2 Symptomatic: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
8.3 Asymptomatic
8.3.1 Overview
8.3.2 Asymptomatic: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Body Fluid
9.1 Overview
9.2 Blood
9.2.1 Overview
9.2.2 Blood: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9.3 Urine
9.3.1 Overview
9.3.2 Urine: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9.4 Saliva
9.4.1 Overview
9.4.2 Saliva: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9.5 Stomach Wash/Gastric Juice
9.5.1 Overview
9.5.2 Stomach Wash/Gastric Juice: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9.6 Tissue
9.6.1 Overview
9.6.2 Tissue: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
9.7 Other
9.7.1 Overview
9.7.2 Other: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
10. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Procedures
10.1 Overview
10.2 Endoscopic Procedure
10.2.1 Overview
10.2.2 Endoscopic Procedure: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
10.2.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Endoscopic Procedures, by Type, 2019–2028 (US$ Million)
10.3 Biopsy and Tissue Tests
10.3.1 Overview
10.3.2 Biopsy and Tissue Tests: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Lab Tests
10.4.1 Overview
10.4.2 Lab Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
10.4.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Lab Tests, by Type, 2019–2028 (US$ Million)
10.5 In-Vitro Diagnostic Tests
10.5.1 Overview
10.5.2 In-Vitro Diagnostic Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
10.5.2.1 United States Gastric Cancer Diagnostic Procedure Market, by In-Vitro Diagnostic Tests, by Type, 2019–2028 (US$ Million)
10.6 Imaging Tests
10.6.1 Overview
10.6.2 Imaging Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
10.6.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Imaging Tests, by Type, 2019–2028 (US$ Million)
10.7 Molecular Diagnostics
10.7.1 Overview
10.7.2 Molecular Diagnostics: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
10.7.2.1 United States Gastric Cancer Diagnostic Procedure Market, by Molecular Diagnostic, by Type, 2019–2028 (US$ Million)
10.8 Multiplexing Molecular Diagnostics and Immunoassay
10.8.1 Overview
10.8.2 Multiplexing Molecular Diagnostics and Immunoassay: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
10.9 Others
10.9.1 Overview
10.9.2 Others: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
11. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Offerings
11.1 Overview
11.2 Instruments
11.2.1 Overview
11.2.2 Instruments: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
11.3 Reagents and Consumables
11.3.1 Overview
11.3.2 Reagents and Consumables: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Services
11.4.1 Overview
11.4.2 Services: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
12. United States Gastric Cancer Diagnostic Procedure Market Analysis – by Disease Indication
12.1 Overview
12.2 Early Gastric Cancer
12.2.1 Overview
12.2.2 Early Gastric Cancer: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
12.3 Gastric Cancer Advanced Types
12.3.1 Overview
12.3.2 Gastric Cancer Advanced Types: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
13. United States Gastric Cancer Diagnostic Procedure Market: Impact Assessment of COVID-19 Pandemic
13.1 US: Impact Assessment of COVID-19 Pandemic
14. United States Gastric Cancer Diagnostic Procedure Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in United States Gastric Cancer Diagnostic Procedure Market (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 Atlas-Link Biotech Co Ltd
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Bio-Rad Laboratories Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 MiRXES Pte Ltd
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Agilent Technologies Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 F. Hoffmann-La Roche Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 bioMerieux SA
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Thermo Fisher Scientific Inc
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Illumina Inc
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Vela Diagnostics Holding Pte Ltd
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Myraid Genetics Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. United States Gastric Cancer Diagnostic Procedure Market, by Diagnostic Laboratories, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. United States Gastric Cancer Diagnostic Procedure Market, by Hospitals, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. United States Gastric Cancer Diagnostic Procedure Market, by Cancer Research Institutes, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 4. United States Gastric Cancer Diagnostic Procedure Market, by Oncology Specialty Clinics, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. United States Gastric Cancer Diagnostic Procedure Market, by Others, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. United States Gastric Cancer Diagnostic Procedure Market, by Endoscopic Procedures, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. United States Gastric Cancer Diagnostic Procedure Market, by Lab Tests, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. United States Gastric Cancer Diagnostic Procedure Market, by In-Vitro Diagnostic Tests, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. United States Gastric Cancer Diagnostic Procedure Market, by Imaging Tests, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. United States Gastric Cancer Diagnostic Procedure Market, by Molecular Diagnostic, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 11. Organic Developments in the United States Gastric Cancer Diagnostic Procedure Market
Table 12. Inorganic Developments in the United States Gastric Cancer Diagnostic Procedure Market
Table 13. Glossary of Terms
LIST OF FIGURES
Figure 1. Gastric Cancer Diagnostic Procedure Market Segmentation
Figure 2. United States Gastric Cancer Diagnostic Procedure Market Overview
Figure 3. Asymptomatic Held Largest Share of Gastric Cancer Diagnostic Procedure Market
Figure 4. United States Gastric Cancer Diagnostic Procedure Market, Industry Landscape
Figure 5. US PEST Analysis
Figure 6. Expert Opinion
Figure 7. Gastric Cancer Diagnostic Procedure Market Impact Analysis of Drivers and Restraints
Figure 8. United States Gastric Cancer Diagnostic Procedure Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. Market Positioning of Key Players in United States Gastric Cancer Diagnostic Procedure Market
Figure 10. United States Gastric Cancer Diagnostic Procedure Market, by Healthcare Providers, 2021 & 2028 (%)
Figure 11. Diagnostic Laboratories: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Hospitals: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Cancer Research Institutes: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Oncology Specialty Clinics: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Others: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. United States Gastric Cancer Diagnostic Procedure Market, by Symptom Type, 2021 & 2028 (%)
Figure 17. Symptomatic: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 18. Asymptomatic: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 19. United States Gastric Cancer Diagnostic Procedure Market, by Body Fluid, 2021 & 2028 (%)
Figure 20. Blood: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 21. Urine: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 22. Saliva: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 23. Stomach Wash/Gastric Juice: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 24. Tissue: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 25. Other: Gastric Cancer Diagnostic Procedure Market– Revenue and Forecast to 2028 (US$ Million)
Figure 26. United States Gastric Cancer Diagnostic Procedure Market, by Procedures, 2021 & 2028 (%)
Figure 27. Endoscopic Procedure: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Biopsy and Tissue Tests: United States Gastric Cancer Diagnostic Procedure Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Lab Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. In-Vitro Diagnostic Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Imaging Tests: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Molecular Diagnostics: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Multiplexing Molecular Diagnostics and Immunoassay: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Others: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. United States Gastric Cancer Diagnostic Procedure Market, by Offerings, 2021 & 2028 (%)
Figure 36. Instruments: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Reagents and Consumables: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Services: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. United States Gastric Cancer Diagnostic Procedure Market, by Disease Indication, 2021 & 2028 (%)
Figure 40. Early Gastric Cancer: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Gastric Cancer Advanced Types: United States Gastric Cancer Diagnostic Procedures Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Impact of COVID-19 Pandemic on US Gastric Cancer Diagnostic Procedure Market
Figure 43. Growth Strategies in United States Gastric Cancer Diagnostic Procedure Market (%)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the United States gastric cancer diagnostic procedure market.
● Highlights key business priorities in order to assist companies to realign their business strategies.
● The key findings and recommendations highlight crucial progressive industry trends in the United States gastric cancer diagnostic procedure market, thereby allowing players across the value chain to develop effective long-term strategies.
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
● Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
The List of Companies – United States Gastric Cancer Diagnostic Procedure Market
● Atlas-Link Biotech Co Ltd
● Bio-Rad Laboratories Inc
● MiRXES Pte Ltd
● Agilent Technologies Inc
● F. Hoffmann-La Roche Ltd
● bioMerieux SA
● Thermo Fisher Scientific Inc
● Illumina Inc
● Vela Diagnostics Holding Pte Ltd
● Myraid Genetics Inc.
According to our latest study on “United States Gastric Cancer Diagnostic Procedures Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Healthcare Providers, Symptom Types, Body Fluids, Procedures, Offerings, and Disease Indication,” the market is expected to grow from US$ 481.37 million in 2022 to US$ 637.84 million by 2028; it is estimated to record a CAGR of 4.8% from 2022 to 2028. The rise in the prevalence of gastrointestinal (GI) diseases and the growing aging population drive the growth of the United States gastric cancer diagnostic procedure market. However, the shortage of medical laboratory professionals hinders the market growth.
Rising Prevalence of Gastrointestinal Diseases Drives Market Growth
Heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhea are among the common digestive problems. GI diseases account for substantial healthcare utilization and spending. The stomach is lined with a mucous membrane composed of cells and glands. The cells are prone to inflammation leading to peptic ulcers, which can cause gastric cancer. Problems associated with stomach acid backing up into the esophagus, known as gastroesophageal reflux disease (GERD), also increase the risk of developing gastric cancer. As per the American College of Gastroenterology, GERD is one the most common gastrointestinal diseases, and around 20% of the US population suffers from GERD.
Western countries, such as the US and Canada, are reporting a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fiber. As per the Centers for Disease Control and Prevention, in December 2022, ~37.2 million cases of digestive system diseases are recorded in physician offices in the US.
IBD is a term for two conditions—ulcerative colitis and Crohn’s disease. Moreover, in the last few years, cases of IBD have increased worldwide due to a sedentary lifestyle; changing dietary habits; stress; and poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. As per the Crohn’s & Colitis Foundation of America, IBD affects ~1.6 million Americans. Around 70,000 new cases of IBD are diagnosed every year in the US. Further, chronic inflammation and reduced immunosurveillance caused due to IBD may contribute to the development of gastric cancer.
The prevalence of Irritable Bowel Syndrome (IBS) has increased across the world in the last few decades. According to the International Foundation for Gastrointestinal Disorders, Inc., IBS is the most common functional GI disorder, with a prevalence rate of 10–15% across the world. Also, physicians in the US record around 2.4–3.5 million visits of IBS patients annually.
Thus, the increasing prevalence of gastrointestinal (GI) disease increases the risk of developing gastric cancer, which drives the growth of the United States gastric cancer diagnostic procedure market.
Shortage of Medical Professionals Hinders Market Growth
Laboratory tests are crucial to detect, diagnose, and monitor diseases. The test results influence clinical decisions regarding preference for surgery or chemotherapy and patient discharge from a hospital stay. However, producing test results rapidly is challenging. A constant rise in the number of patients and a greater number of available tests lead to an increase in samples headed to the lab. There is a shortage of staff to process these samples and keep up with the rising demand. The Bureau of Labor Statistics (BLS) projected that the US would need a 13% average increase in medical laboratory technologists and technicians between 2016 and 2026, nearly double the underlying average increase in all other occupations of 7%. Further, the US Department of Health and Human Services, Human Resources and Service Administration (HRSA) projects a 22% increase in demand for medical and clinical laboratory technologists and technicians between 2012 and 2025.
Thus, the shortage of medical laboratory professionals hinders the growth of the United States gastric cancer diagnostic procedures market.
Healthcare Providers-Based Insights
The United States gastric cancer diagnostic procedure market, based on healthcare providers, is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. In 2021, the hospitals segment held the largest share of the market. The market for the cancer research institutes segment is expected to grow at the highest rate in the coming years.
Symptom Types-Based Insights
The United States gastric cancer diagnostic procedure market, by symptom types, is bifurcated into symptomatic and asymptomatic. In 2021, the asymptomatic segment held a larger market share. Moreover, the symptomatic segment is estimated to register a higher CAGR during the forecast period.
Body Fluid-Based Insights
The United States gastric cancer diagnostic procedure market, by body fluid, is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. In 2021, the blood segment held the largest share of the market. However, the market for the tissue segment is expected to grow at the highest rate in the coming years.
Procedure-Based Insights
The United States gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics and immunoassays, and others. In 2021, the imaging tests segment held the largest share of the market. The market for the biopsy and tissue tests segment is expected to grow at the highest rate in the coming years.
Offerings-Based Insights
The United States gastric cancer diagnostic procedure market, based on offerings, is segmented into instruments, reagents and consumables, and services. In 2021, the reagents and consumables segment held the largest share of the market. The market for the services segment is expected to grow at the highest rate in the coming years.
Disease Indication-Based Insights
The United States gastric cancer diagnostic procedure market, based on disease indication, is segmented into early gastric cancer and advanced gastric cancer. In 2021, the advanced gastric cancer segment held a larger share of the market. The market for the same segment is expected to grow at a higher rate in the coming years.
Atlas-Link Biotech Co Ltd, Bio-Rad Laboratories Inc, MiRXES Pte Ltd, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, bioMerieux SA, Thermo Fisher Scientific Inc, Illumina Inc, Vela Diagnostics Holding Pte Ltd, and Myraid Genetics Inc. are among the leading companies operating in the United States gastric cancer diagnostic procedure market.
Related Reports
- $3,000.00 – $5,000.00
